[CONTENU PARTENAIRE] In the field of logistics, which is dedicated to the life sciences and in particular research and clinical trials, is a highly regulated niche market. CRYOPDP offers customized domestic and international transport solutions for temperature sensitive cargo. Cédric Picot, President and CEO of CRYO PDP, answers our questions.
Can you introduce CRYOPDP ?
CRYOPDP, launched in 2015, offers international transport solutions for clinical trials and niche therapeutic sectors such as cell and gene therapy. We mainly work with pharmaceutical laboratories, but also with ETI and SMEs such as some biotech companies in France and Europe. CRYOPDP also works with many service providers in the pharmaceutical industry, for example for the production of drugs or the distribution of experimental therapies, including all necessary logistics. Today, our 300 employees work in 13 countries on 3 continents. We operate in more than 140 countries worldwide through our various sites in Europe (England, France, Netherlands, Belgium, Portugal, Poland, Germany), USA, Asia (India, Singapore, Philippines, Japan, South Korea). ) and Australia.
This niche market is heavily regulated. What are the main restrictions to follow?
Today, CRYOPDP transports experimental drugs around the world at controlled temperatures. The different temperature ranges we cover are also subject to different restrictions depending on the country, season and type of product being transported. For example, funds deployed in Moscow in winter will not be the same in India in summer. Therefore, it is important to constantly adapt to the requirements of our customers and always be strict.
Do you have other features?
CRYOPDP can also take care of the repatriation of biological samples taken, regardless of geography, to our customers’ central laboratories. We are also required to regularly intervene in certain clinical trials by delivering them directly to patients’ homes. To do this, we have a special service that manages these logistical aspects and guarantees the confidentiality of patient information. In general, the clinical research sector and niche therapies are particularly sensitive. Our clients require logistics and operational efficiency to be close to 100%. In the tasks entrusted to us, there is always a patient waiting for either treatment or a result, so any mistake is unthinkable.
What are the problems in your market?
The main challenge remains to ensure the global coverage of our services. Today, our clients are major players in either clinical research or cell and gene therapy. However, very often clinical trials are carried out on the scale of several continents. We must be present everywhere with quality service and efficient processes to respond to the research protocols entrusted to us.
Like other fields of activity, do you face difficulties in terms of hiring?
It is difficult for us to hire qualified specialists in our field of activity, especially in Europe and the USA. We are looking for two types of professionals: supply chain experts from the pharmaceutical and life sciences industries, as well as internationally qualified logisticians with in-depth knowledge of customs regulations and the types of very specific samples we transport. This shortfall is partly due to the lack of training in our sector. To remedy this, we often recruit motivated juniors that we train. We also place great emphasis on internal promotion of our talents.
What are the trends in your market?
The market for clinical trials is constantly growing around the world, in part because research is evolving. This is good news. In addition, the scope of clinical research is expanding to include new technologies such as messenger RNA. Over the past ten years, we have also seen the development of research on rare and orphan diseases.
Clinical trials are increasingly being conducted in emerging economies for populations that respond positively to experimental treatments. This requires more complex logistics as we operate in new and sometimes challenging geographies such as Asia, Africa and Latin America.
Finally, the presence of biological elements in experimental treatments also increases. However, these are sensitive elements in terms of temperature. As such, CRYOPDP offers a wide range of temperature solutions to meet these new demands, ranging from cryogenics for specific therapies to so-called controlled ambient temperatures.
Has the Covid-19 pandemic affected your business?
This had serious consequences! At the very beginning of the pandemic, when countries closed borders and suspended flights, it was necessary to find other ways to deliver biological samples and experimental drugs. The CRYOPDP teams were able to respond quickly and efficiently to reinvent our operating model overnight. We turned to road transport or special air means. Years of supply chain experience and the systematic implementation of Business Continuity Plans (BCP) to ensure patient delivery and service have enabled us to maintain 100% of our worldwide operations without any interruption during this crisis.
Another consequence of the crisis has to do with consumer demand itself, which has diversified. CRYOPDP is actively involved in Covid-19 clinical research. We have also been asked to supply exceptional medicines, antivirals and antibiotics in bulk to different countries.
This content was created with SCRIBEO. The editors of BFMBUSINESS did not take part in the production of this content.